{"id":"cyclophosphamide-methotrexate-5-fu","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Bone marrow suppression"},{"rate":"30-60%","effect":"Nausea and vomiting"},{"rate":"20-50%","effect":"Mucositis"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL88","moleculeType":"Small molecule","molecularWeight":"261.09"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, causing cross-linking and interfering with DNA replication. Methotrexate inhibits dihydrofolate reductase, an enzyme necessary for DNA synthesis and cell replication. 5 FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis.","oneSentence":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:16.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":"Metastatic Breast Cancer, Tumor, Muscle Neoplasms","enrollment":100},{"nctId":"NCT00309569","phase":"PHASE3","title":"Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1991-10","conditions":"Early Stage Breast Cancer","enrollment":429},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT00331097","phase":"PHASE3","title":"ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2003-07","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00024102","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Breast Cancer","enrollment":633},{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720},{"nctId":"NCT01204437","phase":"PHASE2, PHASE3","title":"Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2009-03","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT01998906","phase":"PHASE3","title":"A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-05","conditions":"Breast Cancer","enrollment":330},{"nctId":"NCT00002784","phase":"PHASE3","title":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1996-06","conditions":"Breast Cancer","enrollment":344},{"nctId":"NCT00003549","phase":"PHASE2","title":"S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-10","conditions":"Neuroendocrine Carcinoma of the Skin","enrollment":80},{"nctId":"NCT00002524","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1993-06","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT00174655","phase":"PHASE3","title":"BIG 02/98 Docetaxel - Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"1998-06","conditions":"Breast Neoplasms","enrollment":2887},{"nctId":"NCT00152191","phase":"PHASE3","title":"A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"1996-10","conditions":"Breast Cancer","enrollment":1300},{"nctId":"NCT00193011","phase":"PHASE3","title":"Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2002-03","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT00124111","phase":"PHASE2","title":"A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00001498","phase":"PHASE2","title":"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-02","conditions":"Breast Cancer, Breast Neoplasms","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cyclophosphamide, Methotrexate, 5 FU","genericName":"Cyclophosphamide, Methotrexate, 5 FU","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and 5 FU is a thymidylate synthase inhibitor. Used for Breast cancer, Lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}